Clinical trials: Anthracyclines
Breast Cancer
Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer
Doxorubicin and other anthracyclines are commonly used to treat breast cancer and other types of cancer. Unfortunately, they can cause heart muscle damage, resulting in scarring, abnormal contraction and relaxation, and heart…
- Trial name
- NCT01708798
- Testing
- Eplerenone
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- University of British Columbia
Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes
A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
This study tests a new treatment approach for people with early-stage triple negative breast cancer whose tumors have a high number of immune cells, called tumor-infiltrating lymphocytes or TILs, as seen by a pathologist on…
- Trial name
- NeoTILs (NCT07743190)
- Testing
- Carboplatin, Paclitaxcel, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Medical University of South Carolina
Cancer, Breast Cancer
Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine (Xeloda) provides measurable clinical benefits over capecitabine alone in women with metastatic breast cancer.
- Trial name
- NCT00082433
- Testing
- Ixabepilone + Capecitabine, Capecitabine
- Where
- 186 sites in United States, Argentina and 27 more
- Volunteers
- 1,221 people
- Sponsor
- R-Pharm
Breast Neoplasms
Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients
The primary objective of this study is to assess the pathological Complete Response (pCR) rate by treatment arm (according to Chevallier criteria).
- Trial name
- SATIN (NCT00485979)
- Testing
- larotaxel (XRP9881), docetaxel, trastuzumab
- Where
- 8 sites in Belgium, Brazil and 6 more
- Volunteers
- 330 people
- Sponsor
- Sanofi
Hodgkin Disease, Lymphoma, Non-Hodgkin
Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma
This study is to inquire by mailed survey regarding the cardiac and general health of patients previously treated for Hodgkin's and non-Hodgkin's lymphoma with radiation therapy/anthracycline chemotherapy.
- Trial name
- NCT00903890
- Testing
- Survey
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Rochester
Breast Cancer
Natriuretic Peptide Concentrations of B-type (BNP) During Anesthesia in Patients Previously Sensitized to Anthracyclines
The cardiotoxicity of anthracyclines chemotherapy remains a major problem, despite clinical and echocardiographic monitoring. In the case of treatment for breast cancer, surgery requiring general anesthesia may follow…
- Trial name
- PEP-NAT-B (NCT01754597)
- Testing
- Dosage of B-type natriuretic peptide (NT-proBNP)
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Institut Bergonié
Breast Cancer
NeoSAMBA: Neoadjuvant: Does the Sequence of Anthracycline and Taxane Matters: Before or After?
The purpose of this study is to evaluate the usual and the reverse sequence of an anthracycline followed by a taxane in locally advanced breast cancer.
- Trial name
- NeoSAMBA (NCT01270373)
- Testing
- FAC x 3 followed by Docetaxel x 3, Docetaxel x 3 followed by FAC x 3
- Where
- Brazil
- Volunteers
- 112 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
Participants Undergoing Anthracycline Chemotherapy
Remote Ischemic Conditioning in Oncology
This is a feasibility study at a single site, Cincinnati Children's Hospital Medical Center. Patients undergoing anthracycline chemotherapy for Hodgkin disease and soft-tissue and bone sarcoma who meet eligibility requirements…
- Trial name
- RICO (NCT04805346)
- Testing
- autoRIC®
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Cardiomyopathy
Prevention of Anthracycline or Trastuzumab Induced Cardiomyopathy by Metoprolol
The primary objective of this study is to investigate whether giving prophylactic metoprolol prior to and during anthracycline or trastuzumab therapy will decrease the incidence of anthracycline-induced cardiomyopathy.
- Trial name
- NCT00806390
- Testing
- Metoprolol
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Maryland, Baltimore
Breast Cancer, Doxorubicin Induced Cardiomyopathy
Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
This study aims to evaluate the efficacy and safety of telmisartan as a cardioprotective agent in patients receiving doxorubicin-based chemotherapy, with the goal of reducing treatment-associated cardiotoxicity, optimizing…
- Trial name
- NCT07370506
- Testing
- Telmisartan, Doxorubicin (DOX)
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Tanta University
Extravasation
A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines
The purpose of this study is To prevent progression of a lesion caused by anthracycline extravasation into necrosis, which would require surgical intervention To prevent development of deep tissue necrosis and destruction leading…
- Trial name
- NCT00548704
- Testing
- Dexrazoxane
- Where
- 34 sites in Denmark, Germany and 3 more
- Volunteers
- 57 people
- Sponsor
- Valerio Therapeutics
Cardiac Complications
Magnetic Resonance Imaging:A Window to Anthracycline Toxicity
The study is being conducted to see which cardiac tests that monitor how the heart functions during and after treatment with anthracyclines are most effective.
- Trial name
- NCT03211520
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Connecticut Children's Medical Center
Breast Cancer
Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer
The purpose of this research study is to compare the efficacy and safety of EG12014 with Herceptin as neoadjuvant treatment for 12 weeks, followed by surgery and subsequent EG12014 or Herceptin adjuvant treatment for up to 12…
- Trial name
- NCT03433313
- Testing
- EG12014, Herceptin
- Where
- 91 sites in United States, Belarus and 9 more
- Volunteers
- 807 people
- Sponsor
- EirGenix, Inc.
Breast Cancer
Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular Magnetic Resonance (MR)
Consecutive patients with a first diagnosis of breast cancer will be identified at the Tom Baker Cancer Centre (TBCC) and included into the study, if they are going to receive chemotherapy with anthracyclines and / or Trastuzumab…
- Trial name
- Cardiotox (NCT00679874)
- Testing
- Cardio-vascular MRI
- Where
- Canada
- Volunteers
- 66 people
- Sponsor
- University of Calgary
Anthracycline Induced Cardiotoxicity
Spironolactone Against Anthracycline-induced Cardiomyopathy
This study sought to investigate the whether spironolactone protects the heart against anthracycline-induced cardiotoxicity.
- Trial name
- NCT02053974
- Testing
- Spironolactone
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people
- Sponsor
- TC Erciyes University
Breast Cancer
BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00049244
- Testing
- capecitabine, ixabepilone
- Where
- United States
- Sponsor
- R-Pharm
Diffuse Large B Cell Lymphoma
Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy
The purpose of this trial is to compare the efficacy and safety of Inotuzumab Ozogamicin in combination with R-CVP with that of R-G-CVP for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) in a population of patients not…
- Trial name
- INCA (NCT01679119)
- Testing
- Cyclophosphamide, Vincristine, Prednisolone
- Where
- 40 sites in United Kingdom
- Volunteers
- 129 people
- Sponsor
- University College, London
Newly Diagnosed AML With FLT3 Activating Mutations
A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
This pilot study is designed to evaluate the safety and tolerability of oral crenolanib besylate given sequentially during standard induction and consolidation chemotherapy in patients with newly diagnosed AML with FLT3…
- Trial name
- NCT02283177
- Testing
- crenolanib, cytarabine, daunorubicin
- Where
- 9 sites in United States
- Volunteers
- 44 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Nausea, Vomiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
The purpose of this study is to check how well LY35327021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy.
- Conditions
- Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
- Trial name
- NCT07169851
- Testing
- LY3537021, Standard of Care Antiemetic Therapies, Background Chemotherapy
- Where
- 67 sites in United States, Australia and 8 more
- Volunteers
- 204 people
- Sponsor
- Eli Lilly and Company
Breast Cancer, Heart Failure
CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of cancer therapeutics-related cardiac dysfunction in patients with breast cancer receiving anthracycline treatment.
- Trial name
- PROTECTAA (NCT06304857)
- Testing
- Dapagliflozin
- Where
- 3 sites in Poland
- Volunteers
- 188 people
- Sponsor
- 4th Military Clinical Hospital with Polyclinic, Poland